Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia

Prostate

Volumn 48, Issue 1, 2001, Pages 16-28

  Bruce Malkowicz, S ^a   McKenna, W Gillies ^b   Vaughn, David J ^a   Wan, X Steven ^b   Propert, Kathleen J ^a   Rockwell, Kenneth ^c   Marks, Sheldon H F ^d   Wein, Alan J ^a   Kennedy, Ann R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d Arizona Urologic Specialists   (United States)

Author keywords

Benign prostatic hyperplasia (BPH); Bowman Birk inhibitor; Prostate specific antigen

Indexed keywords

BOWMAN BIRK INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOYBEAN; SYMPTOMATOLOGY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT OBSTRUCTION;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; TREATMENT OUTCOME; TRIGLYCERIDES; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; URINARY RETENTION;

EID: 0035876208     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1077     Document Type: Article

References (37)

1. Anticarcinogenic activity of protease inhibitors: Overview
2. Preparation and production of a cancer chemopreventive agent, Bowman-Birk Inhibitor Concentrate
3. Chemopreventive agents: Protease inhibitors
4. Single dose administration of Bowman-Birk Inhibitor Concentrate (BBIC) in patients with oral leukoplakia
5. Bowman-Birk Inhibitor Concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels and proteolytic activity in buccal mucosal cells
6. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman-Birk inhibitor
7. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk Inhibitor Concentrate in a phase IIa chemoprevention trial
8. The natural history and course of untreated benign prostatic hyperplasia
9. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor
10. Inhibition of N-nitrosomethylbenzylamine induced esophageal neoplasms by the Bowman-Birk protease inhibitor
11. Treatment with the soybean-derived Bowman-Birk inhibitor increases the serum prostate specific antigen concentration while suppressing the growth of human prostate cancer xenografts in nude mice
12. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate
13. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent
14. Cancer incidence in Japanese in Japan, Hawaii, and Western United States
15. Cancer epidemiology in populations of the United States with emphasis on Hawaii and California and Japan
16. Dietary trends for vegetable proteins in foods
17. Interracial incidence of benign prostatic hypertrophy
18. Prostatic obstruction in Chinese populations
19. Racial differences found in PSA levels
20. Serum prostate-specific antigen in a community-based population of healthy men
21. Phase I study of oral Bowman-Birk Inhibitor Concentrate (BBIC), a soy protein, on patients with lower urinary tract symptoms
22. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor
23. Urinary excretion of Bowman-Birk inhibitor in humans after soy sonsumption as determined by a monoclonal antibody-based immunoassay
24. Assay of creatinine in serum, with use of Fuller's earth to remove interferents
25. Creatinine assay by the Fuller's earth procedure or by enzymatic determination is adequate for urine but not plasma of mice
26. The effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity
27. The so-called 'placebo effect' in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean caused by censoring
28. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium induced ulcerative colitis
29. The Bowman-Birk protease inhibitor: Trypsin- and chymotrypsin-inhibitor from soybeans
30. Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor
31. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase
32. Sterol regulatory element binding proteins (SREBPs): Controllers of lipid synthesis and cellular uptake
33. Human prostate-specific antigen: Structural and functional similarity with serine proteases
34. Prostate specific antigen (PSA)
35. Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomy